ClinicalTrials.gg
TerminatedNCT01062191ROMUpdated Jun 8, 2011

Altrazeal Range of Motion Study Comparing With Typical Carboxymethyl

An interventional study of Aquacel AG, typical carboxymethylcellulose dressing and Altrazeal Flexible Hydrogel Nanoparticle Wound Dressing in Burn, sponsored by ULURU Inc.. Terminated at 1 site in United States. Open to participants aged 2 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-06-08.

Sponsored by ULURU Inc. · Not applicable, Interventional, and Treatment

How we know

Why this study was terminated
Lack of enrollment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
3
Allocation
Randomized
Ages
2 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 336 studies in Burns with a site in United States — 40 open to participants now, 51 under way, 5 of them phase 3. Burns · United States.

Enrollment
230th of 272
3 · median 26
Started
2007
with 14 others
No phase
152 of 336
14 open now
Registered
97th of 336
by date

Among the 336 studies in Burns with a site in United States, this one is the 230th largest by enrollment of the 272 interventional ones that give a count, is one of 15 that started in 2007, is one of 152 with no phase, and was the 97th registered.

Burns

906 studies on the registry are indexed under Burns; 165 are open to participants now.

Browse Burns studies →

Open to participants now

40 of the 336 studies in Burns with a site in United States are open now. Recruiting first, the newest first:

35 more — sign in →

All 40 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 87 Burns studies recruiting now, 38 (44%) set no upper age limit and 38 (44%) stop at 75 or younger; 17 take children under 18; 10 take healthy volunteers.

This study: 2 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 336 studies in Burns with a site in United States, or all of them as a file.
02

Study summary

The objective of this study is to evaluate the difference in joint range of motion of a new flexible hydrogel nanoparticle wound dressing compared to typical sodium carboxymethylcellulose dressing Aquacel AG for treatment of partial thickness burns.

Read the detailed description

This is a single center, randomized, single blind therapeutic exploratory study to monitor the range of motion of wounds treated with the new nanoparticle hydrogel dressing compared to the range of motion of wounds treated with existing treatment standard (sodium carboxymethylcellulose dressing) in patients with partial thickness burns. A total of 50 joints will be studied. The patients will be at least 7 years of age.. The Department of Physical Medicine and Rehabilitation at Parkland Hospital and Health System, UT Southwestern, will be asked to enroll enough patients to meet the proposed 50 joint study sites (approximately 3-5 afflicted joints per patient). Children will be included in the patient population if possible. Inclusion criteria for the medical condition will be at least one partial thickness burn that crosses at least one peripheral joint axial to the proximal interphalangeal joints. As a control, the patients will also need to have an unburned contralateral joint without major internal or external joint derangement.

The Primary Investigator will first identify the study site and control site for each patient and take the initial measurements. Trained personnel will apply the bandage to the study site. No secondary bandage will be applied. Typical meticulous wound care and adequate analgesic medical coverage will be provided for the duration of the study. Both the patient and medical staff will be trained on patient use instructions for the dressing. The patients will be monitored for a short time after application of the bandage as part of standard procedure, and the patient is then allowed to go home with instructions for care. Within 2-8 days after application, the dressing will be inspected and range of motion will be measured for both the study site and the control site. Any concomitant treatment (medications, wound care) will be thoroughly documented for the duration of the study. Both dressings are designed to remain on the wound until the bandage falls off, which indicates re-epithelialization of the wound. The dressings should not be removed by the patient or medical staff unless there are signs of infection, deterioration of bandage, or other adverse event. If the bandage falls off, the patient is instructed to immediately call the medical staff.

03

Conditions studied

  • Burn

Browse trials for

Keywords

  • hydrogel
  • dressing
  • burn
  • joint
04

Who can participate

Ages eligible
2 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female patient is at least 2 years of age;
  2. Patient is in general good health;
  3. Patient has partial thickness burn that crosses at least one peripheral joint axial to the proximal interphalangeal joints;
  4. Patient has one unburned contralateral joint without major internal or external joint derangement to be used as control
  5. Patient is willing and able to cooperate with the protocol for 30 days
  6. Patient is capable of provided
  7. Patient provides authorization for use and disclosure of protected health information

Exclusion criteria

Exclusion Criteria:

  1. Age less than 2 years;
  2. Patient has superficial or full thickness burn wounds;
  3. Patient has acutely infected wounds;
  4. Patient has wounds with surrounding cellulites;
  5. Patient has a history of to any components of either the nanoparticle or sodium hydrocellulose dressing, or any know sensitivities to other hydrogel bandage treatments
  6. Patient has a concurrent clinical condition, which in the judgment of the Investigator cold either pose a health risk to the patient while participating in this study, or could potentially influence the outcome of the study;
  7. Patient is wearing any type of orthopedic device that may come in contact with the dressing;
  8. Patient has history of poor wound healing, history of smoking, history of drug/alcohol abuse, any other skin/immune system condition that would increase likelihood of wound irritation, infection or increase chance of early termination
  9. Patient has wound originating from chronic condition
  10. Patients with history of any immunodeficiency syndrome or condition
  11. Patients who have applied any dressing or medication (OTC or prescription) to the wound (within 48 hours of study? )
  12. Patient has participated in a clinical research study within the last 30 days prior to enrollment;
  13. Patient is unable to communicate or to cooperate with the investigator due to language problems, poor mental development, or impaired cerebral function
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
3 participants (actual)

Study arms

  • Experimental
    Altrazeal Flexible Hydrogel Nanoparticle Wound Dressing

    Nanoflex Powder Dressing applied to joint

    Device: Altrazeal Flexible Hydrogel Nanoparticle Wound Dressing

  • Active comparator
    Aquacel AG, typical carboxymethylcellulose dressing

    Sodium CMC dressing control applied to joint

    Device: Aquacel AG, typical carboxymethylcellulose dressing

Interventions

  • DeviceAquacel AG, typical carboxymethylcellulose dressing

    4" X 4", Aquacel silver sheet

  • DeviceAltrazeal Flexible Hydrogel Nanoparticle Wound Dressing

    Wound dressing

06

What researchers measure

Primary outcomes

  1. Range of motion in burned joints with dressing in place as compared to control

    Time frame: Up to 2 weeks

Secondary outcomes

  1. Pain at joint with dressing in place

    Time frame: up to 2 weeks

07

Study locations

1 site
  • UT Southwestern
    Dallas, Texas 75390, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2007, a primary completion of Oct 2008 and a completion of Oct 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 2, 2010
First posted
Feb 4, 2010
Start
May 2007
Primary completionActual
Oct 2008
CompletionActual
Oct 2008
Last update
Jun 8, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 8, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01062191
Lead sponsor
ULURU Inc.
First posted
Feb 4, 2010
Start date
May 2007
Primary completion
Oct 2008
Completion
Oct 2008
Last update
Jun 8, 2011

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion